Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study

Shazli Azmi, Maryam Ferdousi, Uazman Alam, Ioannis N. Petropoulos, Georgios Ponirakis, Andrew Marshall, Omar Asghar, Hassan Fadavi, Wendy Jones, Mitra Tavakoli, Andrew J M Boulton, Maria Jeziorska, Handrean Soran, Nathan Efron, Rayaz Malik

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aims/hypothesis: The aim of this study was to identify the contribution of small- and large-fibre neuropathy to erectile dysfunction in men with type 1 diabetes mellitus. Methods: A total of 70 participants (29 without and 41 with erectile dysfunction) with type 1 diabetes and 34 age-matched control participants underwent a comprehensive assessment of large- and small-fibre neuropathy. Results: The prevalence of erectile dysfunction in participants with type 1 diabetes was 58.6%. After adjusting for age, participants with type 1 diabetes and erectile dysfunction had a significantly higher score on the Neuropathy Symptom Profile (mean ± SEM 5.3 ± 0.9 vs 1.8 ± 1.2, p = 0.03), a higher vibration perception threshold (18.3 ± 1.9 vs 10.7 ± 2.4 V, p = 0.02), and a lower sural nerve amplitude (5.0 ± 1.1 vs 11.7 ± 1.5 mV, p = 0.002), peroneal nerve amplitude (2.1 ± 0.4 vs 4.7 ± 0.5 mV, p < 0.001) and peroneal nerve conduction velocity (34.8 ± 1.5 vs 41.9 ± 2.0 m/s, p = 0.01) compared with those without erectile dysfunction. There was also evidence of a marked small-fibre neuropathy with an impaired cold threshold (19.7 ± 1.4°C vs 27.3 ± 1.8°C, p = 0.003), warm threshold (42.9 ± 0.8°C vs 39.0 ± 0.9°C, p = 0.005) and heart rate variability (21.5 ± 3.1 vs 30.0 ± 3.7 beats/min, p = 0.001) and reduced intraepidermal nerve fibre density (2.8 ± 0.7 vs 5.9 ± 0.7/mm, p = 0.008), corneal nerve fibre density (12.6 ± 1.5 vs 23.9 ± 2.0/mm2, p < 0.001), corneal nerve branch density (12.7 ± 2.5 vs 31.6 ± 3.3/mm2, p < 0.001) and corneal nerve fibre length (8.3 ± 0.7 vs 14.5 ± 1.0 mm/mm2, p < 0.001) in participants with type 1 diabetes and erectile dysfunction. Erectile dysfunction correlated significantly with measures of both large- and small-fibre neuropathy. Conclusions/interpretation: Small-fibre neuropathy is prominent in patients with type 1 diabetes, and is associated with erectile dysfunction and can be objectively quantified using corneal confocal microscopy. This may allow the identification of patients who are less likely to respond to conventional therapies such as phosphodiesterase type 5 inhibitors.

Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalDiabetologia
DOIs
Publication statusAccepted/In press - 29 Mar 2017

Fingerprint

Erectile Dysfunction
Type 1 Diabetes Mellitus
Cross-Sectional Studies
Nerve Fibers
Peroneal Nerve
Phosphodiesterase 5 Inhibitors
Sural Nerve
Small Fiber Neuropathy
Neural Conduction
Vibration
Confocal Microscopy
Heart Rate

Keywords

  • Corneal confocal microscopy
  • Erectile dysfunction
  • Neuropathy
  • Small-fibre neuropathy
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction : a cross-sectional study. / Azmi, Shazli; Ferdousi, Maryam; Alam, Uazman; Petropoulos, Ioannis N.; Ponirakis, Georgios; Marshall, Andrew; Asghar, Omar; Fadavi, Hassan; Jones, Wendy; Tavakoli, Mitra; Boulton, Andrew J M; Jeziorska, Maria; Soran, Handrean; Efron, Nathan; Malik, Rayaz.

In: Diabetologia, 29.03.2017, p. 1-8.

Research output: Contribution to journalArticle

Azmi, S, Ferdousi, M, Alam, U, Petropoulos, IN, Ponirakis, G, Marshall, A, Asghar, O, Fadavi, H, Jones, W, Tavakoli, M, Boulton, AJM, Jeziorska, M, Soran, H, Efron, N & Malik, R 2017, 'Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study', Diabetologia, pp. 1-8. https://doi.org/10.1007/s00125-017-4245-z
Azmi, Shazli ; Ferdousi, Maryam ; Alam, Uazman ; Petropoulos, Ioannis N. ; Ponirakis, Georgios ; Marshall, Andrew ; Asghar, Omar ; Fadavi, Hassan ; Jones, Wendy ; Tavakoli, Mitra ; Boulton, Andrew J M ; Jeziorska, Maria ; Soran, Handrean ; Efron, Nathan ; Malik, Rayaz. / Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction : a cross-sectional study. In: Diabetologia. 2017 ; pp. 1-8.
@article{ecd570f4ce10430b934f36ddece1fea8,
title = "Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study",
abstract = "Aims/hypothesis: The aim of this study was to identify the contribution of small- and large-fibre neuropathy to erectile dysfunction in men with type 1 diabetes mellitus. Methods: A total of 70 participants (29 without and 41 with erectile dysfunction) with type 1 diabetes and 34 age-matched control participants underwent a comprehensive assessment of large- and small-fibre neuropathy. Results: The prevalence of erectile dysfunction in participants with type 1 diabetes was 58.6{\%}. After adjusting for age, participants with type 1 diabetes and erectile dysfunction had a significantly higher score on the Neuropathy Symptom Profile (mean ± SEM 5.3 ± 0.9 vs 1.8 ± 1.2, p = 0.03), a higher vibration perception threshold (18.3 ± 1.9 vs 10.7 ± 2.4 V, p = 0.02), and a lower sural nerve amplitude (5.0 ± 1.1 vs 11.7 ± 1.5 mV, p = 0.002), peroneal nerve amplitude (2.1 ± 0.4 vs 4.7 ± 0.5 mV, p < 0.001) and peroneal nerve conduction velocity (34.8 ± 1.5 vs 41.9 ± 2.0 m/s, p = 0.01) compared with those without erectile dysfunction. There was also evidence of a marked small-fibre neuropathy with an impaired cold threshold (19.7 ± 1.4°C vs 27.3 ± 1.8°C, p = 0.003), warm threshold (42.9 ± 0.8°C vs 39.0 ± 0.9°C, p = 0.005) and heart rate variability (21.5 ± 3.1 vs 30.0 ± 3.7 beats/min, p = 0.001) and reduced intraepidermal nerve fibre density (2.8 ± 0.7 vs 5.9 ± 0.7/mm, p = 0.008), corneal nerve fibre density (12.6 ± 1.5 vs 23.9 ± 2.0/mm2, p < 0.001), corneal nerve branch density (12.7 ± 2.5 vs 31.6 ± 3.3/mm2, p < 0.001) and corneal nerve fibre length (8.3 ± 0.7 vs 14.5 ± 1.0 mm/mm2, p < 0.001) in participants with type 1 diabetes and erectile dysfunction. Erectile dysfunction correlated significantly with measures of both large- and small-fibre neuropathy. Conclusions/interpretation: Small-fibre neuropathy is prominent in patients with type 1 diabetes, and is associated with erectile dysfunction and can be objectively quantified using corneal confocal microscopy. This may allow the identification of patients who are less likely to respond to conventional therapies such as phosphodiesterase type 5 inhibitors.",
keywords = "Corneal confocal microscopy, Erectile dysfunction, Neuropathy, Small-fibre neuropathy, Type 1 diabetes",
author = "Shazli Azmi and Maryam Ferdousi and Uazman Alam and Petropoulos, {Ioannis N.} and Georgios Ponirakis and Andrew Marshall and Omar Asghar and Hassan Fadavi and Wendy Jones and Mitra Tavakoli and Boulton, {Andrew J M} and Maria Jeziorska and Handrean Soran and Nathan Efron and Rayaz Malik",
year = "2017",
month = "3",
day = "29",
doi = "10.1007/s00125-017-4245-z",
language = "English",
pages = "1--8",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction

T2 - a cross-sectional study

AU - Azmi, Shazli

AU - Ferdousi, Maryam

AU - Alam, Uazman

AU - Petropoulos, Ioannis N.

AU - Ponirakis, Georgios

AU - Marshall, Andrew

AU - Asghar, Omar

AU - Fadavi, Hassan

AU - Jones, Wendy

AU - Tavakoli, Mitra

AU - Boulton, Andrew J M

AU - Jeziorska, Maria

AU - Soran, Handrean

AU - Efron, Nathan

AU - Malik, Rayaz

PY - 2017/3/29

Y1 - 2017/3/29

N2 - Aims/hypothesis: The aim of this study was to identify the contribution of small- and large-fibre neuropathy to erectile dysfunction in men with type 1 diabetes mellitus. Methods: A total of 70 participants (29 without and 41 with erectile dysfunction) with type 1 diabetes and 34 age-matched control participants underwent a comprehensive assessment of large- and small-fibre neuropathy. Results: The prevalence of erectile dysfunction in participants with type 1 diabetes was 58.6%. After adjusting for age, participants with type 1 diabetes and erectile dysfunction had a significantly higher score on the Neuropathy Symptom Profile (mean ± SEM 5.3 ± 0.9 vs 1.8 ± 1.2, p = 0.03), a higher vibration perception threshold (18.3 ± 1.9 vs 10.7 ± 2.4 V, p = 0.02), and a lower sural nerve amplitude (5.0 ± 1.1 vs 11.7 ± 1.5 mV, p = 0.002), peroneal nerve amplitude (2.1 ± 0.4 vs 4.7 ± 0.5 mV, p < 0.001) and peroneal nerve conduction velocity (34.8 ± 1.5 vs 41.9 ± 2.0 m/s, p = 0.01) compared with those without erectile dysfunction. There was also evidence of a marked small-fibre neuropathy with an impaired cold threshold (19.7 ± 1.4°C vs 27.3 ± 1.8°C, p = 0.003), warm threshold (42.9 ± 0.8°C vs 39.0 ± 0.9°C, p = 0.005) and heart rate variability (21.5 ± 3.1 vs 30.0 ± 3.7 beats/min, p = 0.001) and reduced intraepidermal nerve fibre density (2.8 ± 0.7 vs 5.9 ± 0.7/mm, p = 0.008), corneal nerve fibre density (12.6 ± 1.5 vs 23.9 ± 2.0/mm2, p < 0.001), corneal nerve branch density (12.7 ± 2.5 vs 31.6 ± 3.3/mm2, p < 0.001) and corneal nerve fibre length (8.3 ± 0.7 vs 14.5 ± 1.0 mm/mm2, p < 0.001) in participants with type 1 diabetes and erectile dysfunction. Erectile dysfunction correlated significantly with measures of both large- and small-fibre neuropathy. Conclusions/interpretation: Small-fibre neuropathy is prominent in patients with type 1 diabetes, and is associated with erectile dysfunction and can be objectively quantified using corneal confocal microscopy. This may allow the identification of patients who are less likely to respond to conventional therapies such as phosphodiesterase type 5 inhibitors.

AB - Aims/hypothesis: The aim of this study was to identify the contribution of small- and large-fibre neuropathy to erectile dysfunction in men with type 1 diabetes mellitus. Methods: A total of 70 participants (29 without and 41 with erectile dysfunction) with type 1 diabetes and 34 age-matched control participants underwent a comprehensive assessment of large- and small-fibre neuropathy. Results: The prevalence of erectile dysfunction in participants with type 1 diabetes was 58.6%. After adjusting for age, participants with type 1 diabetes and erectile dysfunction had a significantly higher score on the Neuropathy Symptom Profile (mean ± SEM 5.3 ± 0.9 vs 1.8 ± 1.2, p = 0.03), a higher vibration perception threshold (18.3 ± 1.9 vs 10.7 ± 2.4 V, p = 0.02), and a lower sural nerve amplitude (5.0 ± 1.1 vs 11.7 ± 1.5 mV, p = 0.002), peroneal nerve amplitude (2.1 ± 0.4 vs 4.7 ± 0.5 mV, p < 0.001) and peroneal nerve conduction velocity (34.8 ± 1.5 vs 41.9 ± 2.0 m/s, p = 0.01) compared with those without erectile dysfunction. There was also evidence of a marked small-fibre neuropathy with an impaired cold threshold (19.7 ± 1.4°C vs 27.3 ± 1.8°C, p = 0.003), warm threshold (42.9 ± 0.8°C vs 39.0 ± 0.9°C, p = 0.005) and heart rate variability (21.5 ± 3.1 vs 30.0 ± 3.7 beats/min, p = 0.001) and reduced intraepidermal nerve fibre density (2.8 ± 0.7 vs 5.9 ± 0.7/mm, p = 0.008), corneal nerve fibre density (12.6 ± 1.5 vs 23.9 ± 2.0/mm2, p < 0.001), corneal nerve branch density (12.7 ± 2.5 vs 31.6 ± 3.3/mm2, p < 0.001) and corneal nerve fibre length (8.3 ± 0.7 vs 14.5 ± 1.0 mm/mm2, p < 0.001) in participants with type 1 diabetes and erectile dysfunction. Erectile dysfunction correlated significantly with measures of both large- and small-fibre neuropathy. Conclusions/interpretation: Small-fibre neuropathy is prominent in patients with type 1 diabetes, and is associated with erectile dysfunction and can be objectively quantified using corneal confocal microscopy. This may allow the identification of patients who are less likely to respond to conventional therapies such as phosphodiesterase type 5 inhibitors.

KW - Corneal confocal microscopy

KW - Erectile dysfunction

KW - Neuropathy

KW - Small-fibre neuropathy

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85016411276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016411276&partnerID=8YFLogxK

U2 - 10.1007/s00125-017-4245-z

DO - 10.1007/s00125-017-4245-z

M3 - Article

C2 - 28357503

AN - SCOPUS:85016411276

SP - 1

EP - 8

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

ER -